These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 35657156)

  • 1. Clinical implications of homologous recombination repair mutations in prostate cancer.
    Cresta Morgado P; Mateo J
    Prostate; 2022 Aug; 82 Suppl 1():S45-S59. PubMed ID: 35657156
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Homologous Recombination Repair Gene Mutations in Prostate Cancer: Prevalence and Clinical Value.
    Fan Y; Liu Z; Chen Y; He Z
    Adv Ther; 2024 Jun; 41(6):2196-2216. PubMed ID: 38767824
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A comprehensive literature review and meta-analysis of the prevalence of pan-cancer BRCA mutations, homologous recombination repair gene mutations, and homologous recombination deficiencies.
    Shao C; Wan J; Lam FC; Tang H; Marley AR; Song Y; Miller C; Brown M; Han J; Adeboyeje G
    Environ Mol Mutagen; 2022 Jul; 63(6):308-316. PubMed ID: 36054589
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Genetic aberrations of homologous recombination repair pathways in prostate cancer: The prognostic and therapeutic implications.
    Saeidi H; Bakrin IH; Raju CS; Ismail P; Saraf M; Khairul-Asri MG
    Adv Med Sci; 2023 Sep; 68(2):359-365. PubMed ID: 37757663
    [TBL] [Abstract][Full Text] [Related]  

  • 5. DNA Repair in Prostate Cancer: Biology and Clinical Implications.
    Mateo J; Boysen G; Barbieri CE; Bryant HE; Castro E; Nelson PS; Olmos D; Pritchard CC; Rubin MA; de Bono JS
    Eur Urol; 2017 Mar; 71(3):417-425. PubMed ID: 27590317
    [TBL] [Abstract][Full Text] [Related]  

  • 6. When and How to Use PARP Inhibitors in Prostate Cancer: A Systematic Review of the Literature with an Update on On-Going Trials.
    Antonarakis ES; Gomella LG; Petrylak DP
    Eur Urol Oncol; 2020 Oct; 3(5):594-611. PubMed ID: 32814685
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification of Novel Biomarkers of Homologous Recombination Defect in DNA Repair to Predict Sensitivity of Prostate Cancer Cells to PARP-Inhibitors.
    Criscuolo D; Morra F; Giannella R; Cerrato A; Celetti A
    Int J Mol Sci; 2019 Jun; 20(12):. PubMed ID: 31242618
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The emerging role of homologous recombination repair and PARP inhibitors in genitourinary malignancies.
    Rimar KJ; Tran PT; Matulewicz RS; Hussain M; Meeks JJ
    Cancer; 2017 Jun; 123(11):1912-1924. PubMed ID: 28323334
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Histologic patterns in prostatic adenocarcinoma are not predictive of mutations in the homologous recombination repair pathway.
    Mahlow J; Barry M; Albertson DJ; Jo YJ; Balatico M; Seasor T; Gebrael G; Kumar SA; Sayegh N; Tripathi N; Agarwal N; Swami U; Sirohi D
    Hum Pathol; 2024 Feb; 144():28-33. PubMed ID: 38278448
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting DNA Repair Defects for Precision Medicine in Prostate Cancer.
    Athie A; Arce-Gallego S; Gonzalez M; Morales-Barrera R; Suarez C; Casals Galobart T; Hernandez Viedma G; Carles J; Mateo J
    Curr Oncol Rep; 2019 Mar; 21(5):42. PubMed ID: 30919167
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PARP inhibitors in advanced prostate cancer: when to use them?
    Díaz-Mejía N; García-Illescas D; Morales-Barrera R; Suarez C; Planas J; Maldonado X; Carles J; Mateo J
    Endocr Relat Cancer; 2021 Jul; 28(8):T79-T93. PubMed ID: 34256353
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Homologous Recombination Repair Gene Variants and Outcomes Among Patients With Prostate Cancer Treated With Poly (ADP-ribose) Polymerase Inhibitors.
    Price MJ; Vashistha V; Winski D; Kelley MJ; Bitting RL; Montgomery B
    JCO Precis Oncol; 2022 Apr; 6(1):e2100461. PubMed ID: 35476551
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Homologous recombination repair gene mutations in Chinese localized and locally advanced prostate cancer patients.
    Jiang X; Hu X; Gu Y; Li Y; Jin M; Zhao H; Gao R; Huang Z; Lu J
    Pathol Res Pract; 2021 Aug; 224():153507. PubMed ID: 34102435
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment of Metastatic Castration-resistant Prostate Cancer: Are PARP Inhibitors Shifting the Paradigm?
    Fujimoto N; Harada K; Shiota M; Tomisaki I; Minato A; Nagata Y; Kimuro R; Harada M; Fujisawa M
    Anticancer Res; 2021 Oct; 41(10):4687-4695. PubMed ID: 34593416
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Practical Guidance on Establishing a Molecular Testing Pathway for Alterations in Homologous Recombination Repair Genes in Clinical Practice for Patients with Metastatic Prostate Cancer.
    Schostak M; Bradbury A; Briganti A; Gonzalez D; Gomella L; Mateo J; Penault-Llorca F; Stenzinger A; Wyatt AW; Bjartell A
    Eur Urol Oncol; 2024 Jun; 7(3):344-354. PubMed ID: 37714762
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Practical considerations for optimising homologous recombination repair mutation testing in patients with metastatic prostate cancer.
    Gonzalez D; Mateo J; Stenzinger A; Rojo F; Shiller M; Wyatt AW; Penault-Llorca F; Gomella LG; Eeles R; Bjartell A
    J Pathol Clin Res; 2021 Jul; 7(4):311-325. PubMed ID: 33630412
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pan-cancer Analysis of Homologous Recombination Repair-associated Gene Alterations and Genome-wide Loss-of-Heterozygosity Score.
    Westphalen CB; Fine AD; André F; Ganesan S; Heinemann V; Rouleau E; Turnbull C; Garcia Palacios L; Lopez JA; Sokol ES; Mateo J
    Clin Cancer Res; 2022 Apr; 28(7):1412-1421. PubMed ID: 34740923
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Frequency and prognostic value of mutations associated with the homologous recombination DNA repair pathway in a large pan cancer cohort.
    Principe DR; Narbutis M; Koch R; Rana A
    Sci Rep; 2020 Nov; 10(1):20223. PubMed ID: 33214570
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Olaparib for the treatment of metastatic prostate cancer.
    Dror CM; Wyatt AW; Chi KN
    Future Oncol; 2021 Jul; 17(19):2413-2429. PubMed ID: 33769071
    [TBL] [Abstract][Full Text] [Related]  

  • 20. PARP Inhibition in Prostate Cancer With Homologous Recombination Repair Alterations.
    von Werdt A; Brandt L; Schärer OD; Rubin MA
    JCO Precis Oncol; 2021; 5():. PubMed ID: 34712892
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.